NDA 050655 · Baxter Hlthcare
Nallpen In Plastic Container
Nafcillin Sodium · Injection
Last checked: Nov 19, 2026Latest source record: Apr 5, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Oct 31, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
3 Phase 3, 2 recruiting
FAERS reports
710
618 serious, 98 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 6, 2024.
INDICATIONS AND USAGE Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY - Susceptibility Test Methods ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to methicillin-resistant Staphylococcus species, therapy with Nafcillin Injection, USP should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin Injection, USP and other antibacterial drugs, Nafcillin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 31, 1989 Original approval · Type 3 - New Dosage Form
2 products under this application
- NALLPEN IN PLASTIC CONTAINER · NAFCILLIN SODIUM EQ 2GM BASE/100ML · INJECTABLE, INJECTION · Prescription
- NALLPEN IN PLASTIC CONTAINER · NAFCILLIN SODIUM EQ 20MG BASE/ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Nafcillin" as an intervention, any sponsor and status, largest first.
- Combination Antibiotic Therapy for Staphylococcus Aureus BacteremiaPivotal-lookingRecruiting
Intermountain Health Care, Inc.Academic, hospital or other
NCT07376889 · 2,096 participants (planned) · Start Feb 1, 2026 · Primary completion Jan 2029
Drug: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Brighton, Colorado; Denver, Colorado; Grand Junction, Colorado · 13 sites in all
- Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream InfectionPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT01191840 · 509 participants · Start Feb 2011 · Primary completion Mar 4, 2017
Drug: Vancomycin; Vancomycin · For: Bacteremia
Sites: Birmingham, Alabama; Los Angeles, California; Denver, Colorado · 15 sites in all
- Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure InfectionsPivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00711802 · 396 participants · Start Jul 23, 2008 · Primary completion Oct 11, 2013
Drug: Daptomycin; Standard of Care (SOC) · For: Skin Diseases, Infectious
Sites: Birmingham, Alabama; Oakland, California; Orange, California · 30 sites in all
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?Pivotal-lookingEnrolling by invitation
West Virginia UniversityAcademic, hospital or other
NCT07148960 · 300 participants (planned) · Start Sep 15, 2025 · Primary completion Jul 2027
Drug: Early Dual IV Antibiotic Therapy - MRSA; Early Dual IV Antibiotic Therapy - MSSA and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Morgantown, West Virginia
- Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)Pivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00077675 · 201 participants · Start Feb 2004 · Primary completion Sep 2004
Drug: Telavancin; vancomycin or antistaphylococcal penicillin · For: Infections, Gram-positive Bacterial
Sites: National City, California
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus BacteremiaPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04775953 · 200 participants · Start Apr 22, 2021 · Primary completion Oct 6, 2023
Drug: Cefazolin; Dalbavancin and 4 more · For: Staphylococcal Bacteraemia
Sites: Birmingham, Alabama; Sacramento, California; Torrance, California · 24 sites in all
- Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)Pivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00061633 · 169 participants · Start Jun 2003 · Primary completion Jan 2004
Drug: Telavancin; Vancomycin or antistaphylococcal penicillin · For: Infections, Gram-Positive Bacterial; Abscess; Burns and 3 more
Sites: Chula Vista, California
- Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)Pivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT01922011 · 149 participants · Start Sep 13, 2013 · Primary completion Jun 14, 2016
Drug: Daptomycin; Vancomycin (or equivalent) and 1 more · For: Acute Hematogenous Osteomyelitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective52
- acute kidney injury48
- rash44
- tubulointerstitial nephritis39
- hypokalaemia38
- renal failure35
- renal failure acute35
- pyrexia34
- drug interaction32
- anxiety25
- drug hypersensitivity25
- nephropathy toxic24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 11 |
| 2006 | 10 |
| 2009 | 15 |
| 2010 | 34 |
| 2011 | 33 |
| 2012 | 44 |
| 2013 | 36 |
| 2014 | 56 |
| 2015 | 35 |
| 2016 | 35 |
| 2017 | 46 |
| 2018 | 42 |
| 2019 | 59 |
| 2020 | 58 |
| 2021 | 41 |
| 2022 | 48 |
| 2023 | 40 |
| 2024 | 18 |
| 2025 | 22 |
| 2026 | 20 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
Prosty C, Noutsios D, Lee TC, et al. · Clin Microbiol Infect 2025 · Systematic Review, Meta-Analysis
- Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin.
Eljaaly K, Alshehri S, Erstad BL · Antimicrob Agents Chemother 2018 · Meta-Analysis, Systematic Review
- Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy.
Norden CW, Bryant R, Palmer D, et al. · South Med J 1986 · Clinical Trial, Controlled Clinical Trial
- Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis.
Yetmar ZA, Razi S, Nayfeh T, et al. · Int J Antimicrob Agents 2022 · Comparative Study, Meta-Analysis
- Controlled trial of cephaloridine, lincomycin, and nafcillin in severe gram-positive coccal infections.
Martin CM, Donohoe RF, Saia JS · Antimicrob Agents Chemother (Bethesda) 1967 · Clinical Trial, Comparative Study
- Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections.
Daly JS, Worthington MG, Andrews RJ, et al. · Antimicrob Agents Chemother 1990 · Clinical Trial, Comparative Study
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.